News Coverage
- 2021
-
November 15, 2021 November 15, 2021 Devimistat Plus Hydroxychloroquine Trial for Soft Tissue Sarcoma Enrolls First Patient
Learn MoreNovember 12, 2021 European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613 (Devimistat)
Learn MoreNovember 11, 2021 Enrollment Begins in Devimistat Trial for Patients With Relapsed Clear Cell Sarcoma
Learn MoreNovember 4, 2021 Devimistat Granted Orphan Drug Designation in Europe for Relapsed/Refractory Burkitt Lymphoma
Learn MoreOctober 13, 2021 Q&A: Sanjeev Luther, Rafael Pharmaceuticals
Learn MoreOctober 4, 2021 Clinical Catch-Up: September 27-October 1
Learn MoreSeptember 27, 2021 Devimistat Now Being Explored for the Treatment of Clear Cell Sarcomas in the United States
Learn MoreSeptember 27, 2021 Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.
Learn MoreSeptember 3, 2021 Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer
Learn MoreAugust 30, 2021 Targeted Oncology: Devimistat With Gemcitabine and Cisplatin Advances to Phase 2 in Biliary Tract Cancer
Learn MoreAugust 30, 2021 BioSpace: Clinical Catch-Up: August 23-27
Learn MoreAugust 19, 2021 Outcomes Rocket: Sanjeev Luther, President & CEO of Rafael Pharmaceuticals: Discovering Therapy Options for Hard-to-Treat and Rare Cancers
Learn MoreJuly 7, 2021 OncLive: Novel Combination May Break Outcomes Stalemate in Pancreatic Cancer
Learn MoreJuly 6, 2021 BioSpace: Clinical Catch-Up: June 28-July 2
Learn MoreJuly 6, 2021 OncLive: Phase 3 ARMADA 2000 Trial of Devimistat in Relapsed/Refractory AML to Continue
Learn MoreJuly 1, 2021 Cancer Network: Devimistat Demonstrates Positive Outcomes in Relapsed/Refractory Acute AML
Learn MoreJuly 1, 2021 Life Science Leader: Against All Odds: Advancing From R&D To Phase 3
Learn MoreJuly 1, 2021 Outsourcing-Pharma: Experts to talk rare and orphan diseases, patient experience at webinar
Learn MoreApril 15, 2021 OncLive: Novel Agents Move the Needle Forward in Metastatic Pancreatic Cancer
Learn MoreApril 5, 2021 BioSpace: Clinical Catch-Up: March 29-April 2
Learn MoreApril 2, 2021 Targeted Oncology: Enrollment Milestone Reached for Phase 3 Study of Devimistat in AML
Learn MoreMarch 22, 2021 Applied Clinical Trials: Cancer Won’t Wait for COVID to End: Conducting Trials Amid the Coronavirus Pandemic
Learn MoreMarch 18, 2021 Healthline: Why Are So Few Black People Included in Cancer Drug Trials?
Learn MoreMarch 17, 2021 BioSpace: Get to Know Sanjeev Luther, CEO and Board Member of Rafael Pharmaceuticals
Learn MoreMarch 15, 2021 OncLive: Investigators Focus Devimistat Study on Older Patients With AML
Learn MoreJanuary 25, 2021 Healio: FDA grants priority review, fast track status to several hematology/oncology products
Learn More - 2020
-
December 31, 2020 Healio: Top in hem/onc: Cancer care amid COVID-19, tumor bed boost
Learn MoreDecember 23, 2020 Healio: 10 FDA actions that may impact your practice
Learn MoreDecember 21, 2020 Healio: FDA grants fast track designation to CPI-613 for AML
Learn MoreDecember 17, 2020 Oncology Nursing News: Devimistat Granted Fast Track Designation for AML Treatment
Learn MoreDecember 16, 2020 Pharmacy Times: Devimistat Gets FDA Fast Track Designation for Acute Myeloid Leukemia
Learn MoreDecember 15, 2020 BioWorld: Regulatory actions for Dec. 15, 2020
Learn MoreDecember 15, 2020 OncLive: FDA Grants Fast Track Designation to Devimistat for AML
Learn MoreDecember 15, 2020 Targeted Oncology: FDA Grants Fast Track Designation to Devimistat in Acute Myeloid Leukemia
Learn MoreDecember 10, 2020 Outsourcing-Pharma: FDA Grants Orphan Status to Rafael Cancer Drug
Learn MoreDecember 7, 2020 BioSpace: Clinical Catch-Up: November 30-December 4
Learn MoreDecember 2, 2020 Targeted Oncology: A Look Back at the FDA News from November 2020
Learn MoreNovember 25, 2020 Oncology Nursing News: Devimistat Granted Orphan Drug Status for Soft Tissue Sarcoma
Learn MoreNovember 24, 2020 OncLive: Devimistat Granted Orphan Drug Status for Soft Tissue Sarcoma
Learn MoreNovember 21, 2020 Healio: Eight important updates for Pancreatic Cancer Awareness Month
Learn MoreNovember 16, 2020 Healio: FDA Grants Fast Track Designation to CPI-613 for Pancreatic Cancer
Learn MoreNovember 13, 2020 Targeted Oncology: Trending News on Targeted Oncology, Week of November 13, 2020
Learn MoreOctober 29, 2020 Targeted Oncology: FDA Grants Orphan Drug Designation to Devimistat for Soft Tissue Sarcoma
Learn MoreOctober 15, 2020 Authority Magazine: Meet The Disruptors: Sanjeev Luther of Rafael Pharmaceuticals On The Three Things You Need To Shake Up Your Industry
Learn MoreOctober 15, 2020 Pharmaceutical Executive: Episode 67: Succeeding Through Adversity
Learn MoreOctober 12, 2020 BioWorld: The new dealmaking normal, will it continue post-pandemic?
Learn MoreAugust 24, 2020 Targeted Oncology: Promising Phase 3 Study of CPI-613 in Metastatic Pancreatic Cancer Achieves Target Enrollment Early
Learn MoreJuly 27, 2020 ROI-NJ: Some Local Firms Hope to Bring Bigger Portion of Pharma Manufacturing Back to U.S. — and N.J.
Learn MoreJune 22, 2020 OncLive: Dr. Alistar on the Need to Develop Biomarkers in Pancreatic Cancer
Learn MoreJune 9, 2020 OncLive: Philip Highlights Promise of Devimistat in Pancreatic Cancer
Learn MoreMay 25, 2020 The Jerusalem Post: Despite COVID-19, Pivotal Pancreatic Cancer Study in Israel Hits Benchmark
Learn MoreApril 30, 2020 RARECast: Targeting the Metabolism of Rare Cancers
Learn MoreApril 28, 2020 Clinical Leader: COVID-19 Presents Unique Challenges For Oncology Trials
Learn MoreApril 8, 2020 Empowered Patient Podcast: Developing Cancer Metabolism Drugs with Sanjeev Luther Rafael Pharmaceuticals
Learn MoreMarch 9, 2020 National Center for Biotechnology Information: The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Learn MoreMarch 7, 2020 OncLive: Dr. Mettu on the Potential of CPI-613 in Metastatic Pancreatic Cancer
Learn More - 2019
-
December 3, 2019 Targeted Oncology: Phase II Devimstat Study Expanded to Increase Access for Patients With Burkitts Lymphoma/Leukemia
Learn MoreNovember 10, 2019 Huffington Post: 13 Unexpected Reasons Why You Might Have A Fever
Learn MoreOctober 31, 2019 Clinical Leader: Rafael Pharmaceuticals Is Starving Cancer Cells
Learn MoreOctober 9, 2019 Targeted Oncology: New Phase III Trial Evaluates Devimistat Plus FOLFIRNOX in Metastatic Pancreatic Cancer
Learn MoreSeptember 5, 2019 Authority Magazine: 5 Things I Wish Someone Told Me Before I Became the CEO of Rafael Pharmaceuticals, With Sanjeev Luther
Learn MoreSeptember 4, 2019 MSN: 30 Things Oncologists Do to Prevent Cancer
Learn MoreAugust 1, 2019 Life Science Leader: Strategies For Success: Developing Drugs For Orphan Diseases
Learn MoreJuly 18, 2019 The Jerusalem Post: Breakthrough Pancreatic Cancer Treatment Phase III Trial opens in Israel
Learn MoreJuly 11, 2019 OncLive: Devimistat Could Have Practice-Changing Potential in Burkitt Lymphoma
Learn MoreJune 11, 2019 DDN News: Special Report on Cancer: Metabolic renaissance?
Learn MoreMay 29, 2019 U.S. News & World Report: Alex Trebek Says His Pancreatic Cancer Is ‘Near Remission’
Learn MoreMay 13, 2019 Winston Salem Journal: Dr. Zanetta Lamar: Cancer metabolism: Gaining momentum in the fight to stop cancer
Learn MoreMarch 29, 2019 Scientific American: A New Way to Fight Cancer
Learn MoreMarch 18, 2019 Investing News Network: Rafael Pharma Stands Out with Drugs Treating Difficult Cancers
Learn MoreMarch 12, 2019 CRAIN’S New York Business: NJ firm advancing drug for pancreatic, hard-to-treat cancers
Learn MoreMarch 7, 2019 OncLive: Dr. Mettu on the Potential of CPI-613® in Metastatic Pancreatic Cancer
Learn More - 2017
-
June 13, 2017 Drug Discovery News: Special Report on Cancer Metabolomics- Into the metabolic maelstrom
Learn MoreMarch 27, 2017 BioWorld: Next-generation oncology: New technologies and MOAs
Learn MoreMarch 24, 2017 BIOCENTURY: How Cornerstone’s CPI-613® leapfrogged to pivotal trials in AML and pancreatic cancer
Learn MoreMarch 23, 2017 MedCity News: Cornerstone gets green light for two pivotal cancer trials
Learn MoreMarch 17, 2017 PM 360 Movers and Shakers: Chi Van Dang, M.D., Ph.D., appointed to Cornerstone’s Board of Directors. Will also serve as Chair of its Scientific and Medical Advisory Boards
Learn MoreFebruary 14, 2017 WCTC-AM: Interview with Sanjeev Luther (COO, Cornerstone Pharmaceuticals)
Learn MoreFebruary 8, 2017 FirstWorld Pharma: Cornerstone Pharmaceuticals Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards
Learn MoreJanuary 30, 2017 BioWorld Appointments and Advancements:- Cornerstone’s new Board of Directors (Subscription Required)
Learn MoreJanuary 16, 2017 The Price of Business Radio: JP Morgan Biotech, Sanjeev Luther (COO, Cornerstone Pharmaceuticals) and Tim Pardee (Chief Oncologist, Cornerstone Pharmaceuticals) on CPI-613®
Learn MoreJanuary 14, 2017 Vital Options International: Dr Zanetta Lamar at ASH 2016- The data collected by Wake Forest Baptist Health
Learn MoreJanuary 14, 2017 Vital Options International: Dr Zanetta Lamar at ASH 2016- The cost of therapy and quality of care
Learn MoreJanuary 14, 2017 Vital Options International: Dr Timothy Pardee at ASH 2016- New Therapeutic Methods
Learn MoreJanuary 14, 2017 Vital Options International: Dr Timothy Pardee at ASH 2016- Addressing patients participating in clinical trials
Learn More - 2016
-
December 5, 2016 ecancer: Dr Timothy Pardee at ASH 2016 on TCA cycle inhibition by CPI-613® in older AML patients
Learn MoreDecember 5, 2016 ecancer: Dr Zanetta Lamar at ASH 2016 on dose escalation of CPI-613® with bendamustine for relapsed T Cell NHL
Learn More - 2015
-
January 9, 2015 OncLive: Dr. Powell at ASH 2014 on CPI-613®, Cytarabine, Mitoxantrone Combo for AML
Learn More - 2014
-
September 11, 2014 OncLive: Dr. Pardee on CPI-613®for Patients With R/R AML
Learn More - 2013
-
December 20, 2013 OncLive: Dr. Pardee Provides an Update on CPI-613® in advanced hematologic malignancies
Learn MoreNovember 1, 2013 Pharmaceutical Business Review: Cornerstone initiates Phase II trial of CPI-613® to treat metastatic pancreatic cancer patients
Learn MoreNovember 1, 2013 Drug Development Technology: Cornerstone begins Phase II study of pancreatic cancer drug
Learn MoreNovember 1, 2013 BioWorld Today: Clinic Roundup (subscription required)
Learn MoreOctober 28, 2013 Drug Development Technology: Cornerstone begins Phase II trial of lung cancer drug
Learn MoreOctober 17, 2013 BioPharma International: Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation
Learn MoreOctober 11, 2013 LymphomaInfo.net: Cornerstone Gets Orphan Drug Status For MDS Treatment
Learn MoreOctober 7, 2013 Medical News Today: Cornerstone Pharmaceuticals receives FDA orphan drug designation of CPI-613® for treatment of myelodysplastic syndrome
Learn MoreOctober 4, 2013 Hematology Times: Drug gets orphan designation for MDS (Registration Required)
Learn MoreOctober 3, 2013 Oncology Times: FDA Grants MDS Drug CPI-613® Orphan Drug Status
Learn MoreOctober 3, 2013 The MDS Beacon: Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation Of CPI-613® For Treatment Of Myelodysplastic Syndrome
Learn MoreJuly 25, 2013 OncLive: Dr. Powell Discusses the Next Steps for CPI-613®
Learn MoreJuly 10, 2013 OncLive: Dr. Pardee on CPI-613® in Hematologic Malignancies
Learn MoreJune 11, 2013 OncLive: Dr. Powell Discusses CPI-613® in Hematologic Malignancies
Learn More - 2011
-
December 14, 2011 Drug Discovery & Development: Cornerstone Releasing CPI-613® Data
Learn MoreDecember 13, 2011 BioWorld Today: ASH Roundup (subscription required)
Learn MoreDecember 6, 2011 Drug Discovery & Development: On Target Delivery
Learn MoreAugust 15, 2011 BioCentury: Powering down cancer
Learn MoreAugust 1, 2011 BioWorld Today: Bench Press (subscription required)
Learn More - 2010
-
November 29, 2010 The New York Times: Fuel lines of tumors are new target
Learn MoreSeptember 1, 2010 Start-Up Magazine: Profile on Cornerstone Pharmaceuticals
Learn MoreAugust 1, 2010 Drug Discovery News: Trends in cancer research
Learn MoreMay 1, 2010 Drug Discovery News: Cancer research turns a corner
Learn More